What happens during vascular surgeries? Why surgeons required vascular patches?
Vascular surgeons perform surgeries to repair congenital heart defects like an atrial septal defects, ventricular septal defects, and ischemic heart disease. Controlling and managing bleeding causes due to incisions or while treating vascular surgeries is a complex and difficult task during surgical interventions. Vascular patches are used to repair lacerations that may have occurred during vascular surgery.
What are vascular patches? What are the different types?
Overview: Vascular patches are used in the surgical repair of blood vessels such as arteries and veins. Vascular patches are used by vascular surgeons in a variety of vascular procedures such as endarterectomy, open abdominal aortic aneurysm repair, vascular bypass surgeries, and so on. Vascular patches are classified into two types based on their material: biological vascular patches and synthetic vascular patches. In comparison to synthetic vascular patches, biological vascular patches are frequently used by cardiac surgeons due to advantages such as superior biocompatibility, ease of use, minimal suture line bleeding, and lower rates of infection.
To know about the assumptions considered for the study download the pdf brochure
What are the pain points of vascular surgeons and physicians?
Patch repair is an important surgical technique in vascular surgery. Patches are used in vascular surgery to repair of blood vessels such as arteries and veins. Choosing an appropriate patch material is a clinical challenge. The current evidence indicates that synthetic and biological materials produce roughly equivalent results. The best option is still unknown, and cardiovascular surgery requires novel biomaterials to repair diseased heart valves or blood vessels.
What solutions/options are available for them?
Patch materials aid cell growth, prevent initial hyperplasia, lower the risk of infection, and eventually degrade once new tissue forms. The majority of companies offer two types of vascular patches: biological vascular patches and synthetic vascular patches.
Biological Vascular Patches: Materials derived from both animal and human sources are used in biologic patches. Bovine pericardium, collagen, and small intestine submucosa are commonly used to make these patches. Biological patches have potential advantages over other materials, such as the ability to remodel into healthy and vascularized tissue, as well as reduce the risk of infection. The following are some of the most important companies that provide biological vascular patches.
Companies
- LeMaitre Vascular
- Edwards Lifesciences Corporation
- Baxter International
- Aziyo Biologics
- Artivion Inc
- Labcor Laboratories LTDA
- Synkromax Biotech Pvt ltd
Products
- XenoSure Biological Vascular Patch
- Duravess Bovine Pericardial Vascular Patch
- Vascu-Guard Peripheral Vascular Patch
- Vascure
- PhotoFix
- Bovine Pericardium Patch
- Synkroscaff
Synthetic Vascular Patches: Artificial materials such as polytetrafluoroethylene, polyester-urethane, and polyethylene terephthalate are used in synthetic vascular patches. These patches are less expensive than biological patches, making them a more affordable option. Synthetic patches have drawbacks, such as an increased risk of infection and hematoma formation. Furthermore, because these patches do not grow with the child's natural tissues, they would require multiple surgeries in the case of congenital heart disease corrective surgeries. The following are some of the most important companies that provide synthetic vascular patches.
Baxter International, LeMaitre Vascular Inc, W.L. Gore & Associates, Getting AB, and B.Braun are the leading companies in this market, accounting for the majority of the market share.
Baxter International: Baxter International is well-represented in North America, Europe, Asia, the Middle East, and Africa. The majority of the company's revenue came from the United States.
LeMaitre Vascular: LeMaitre has a presence in 90 countries worldwide. In order to strengthen its position in the vascular patch market, the company has implemented inorganic strategies. LeMaitre acquired Artegraft's US manufacturing facility in July 2020. The acquisition has allowed the company to strengthen its market offering for biologic vascular patches.
What is the current adoption rate, and why does it fluctuate?
Synthetic patches were more commonly used in vascular surgeries a decade ago than biological patches. Because of the disadvantages of synthetic patches, vascular surgeons are increasingly using biological patches in vascular repair and construction surgeries. When compared to synthetic patches, biological patches have lower infection rates, superior biocompatibility, and increased strength. These benefits of biological patches are expected to boost demand for biological vascular patches in the coming years.
Request a Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=176813375
What does the future of vascular patches look like:
The rising prevalence of cardiovascular diseases such as atherosclerosis and aneurysms is expected to drive up demand for vascular procedures used to diagnose and treat CVDs. The growing popularity of these procedures is expected to drive demand for vascular patches in the coming years.
According to the Centers for Disease Control and Prevention, the most common type of disease is coronary artery disease, which will kill 382,820 people in 2020. According to the British Heart Foundation, as of June 2020, 4 million males and 3.6 million females in the UK suffer from heart and circulatory diseases.
Rapid growth in the global geriatric population is one of the major factors contributing to the rising incidence of a variety of diseases, including CVDs, high cholesterol, hypertension, strokes, and others. Because age is regarded as a major cause of cardiac health deterioration, the aging population is an important indicator of market growth.
According to WHO, by 2030, one out of every six people worldwide will be 60 or older. By 2050, the global population of people aged 60 and up will be twice as large (2.1 billion). Between 2020 and 2050, the number of people aged 80 and up is expected to triple, reaching 426 million. According to the American Heart Association, the incidence of CVD in US men and women aged 40-59 years is 40%, 75% in those aged 60-79 years, and 86% in those over the age of 80.
The availability of reimbursement for vascular procedures has increased the number of vascular surgeries, which is expected to help the vascular patches market grow.
Between 2012 and 2021, medical centre reimbursement (MCA) for impatient procedures increased by 20-26% for carotid endarterectomy (CEA), while professional reimbursement (PR) increased by 3.3% for CEA. In the United States, nearly 70% of patients who require vascular interventions are covered by Medicare.
